LB-30

Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1/2 clinical trial

Derralynn A. Hughes,^{1,2} Sima Canaan-Kühl,³ Sharon Barton,⁴ Richard Collis,⁴ Nicole Sherry⁴

 Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, London, United Kingdom;
University College London, London, United Kingdom;
Department of Medicine, Division of Nephrology, Charité, Universitätsmedizin Campus Mitte, Berlin, Germany;
Freeline Therapeutics, Stevenage, United Kingdom

Disclosure information

Derralynn A. Hughes

I have the following financial relationships to disclose:

Advisory Board: Freeline, Sanofi, Takeda, Amicus, Idorsia

Consulting Fees: Freeline, Sanofi, Takeda, Amicus, Idorsia, Protalix, Sangamo

Honoraria: Freeline, Sanofi, Takeda, Amicus, Idorsia

I will discuss the following investigational use in my presentation: investigational use of FLT190 for the treatment of patients with Fabry disease

MARVEL-1 study sponsor: Freeline Therapeutics

MARVEL-1 is a Phase 1/2 dose-finding trial assessing the safety and efficacy of FLT190 in adult Fabry patients

Adaptive study design* to establish a dose of FLT190 that delivers sustained increases in α-Gal A activity to levels that reduce substrate accumulation

Novel features of MARVEL-1


- · Adaptive dosing design to facilitate dose finding
- Prophylactic immune management regimen to prevent vector-related transaminitis

Design

- Open-label, multicentre, ascending single-dose, Phase 1/2 clinical trial
- One dose of FLT190 administered intravenously over 1-2 hours

Duration

38 weeks for MARVEL-1
5 years for long-term follow-up study (MARVEL-2)
Key inclusion criteria
Adult males (aged ≥18 years)
Classic Fabry disease
Endpoints
Safety, as assessed by AEs
Level of α-Gal A in plasma
Safety as and urine



*Sponsor may expand any dose cohort after discussion with the DMC in order to better characterise the safety profile or α -Gal A response




Patients planned to be dosed in each cohort

Results for Cohort 1 – 7.5 x 10¹¹ vg/kg

Safety

- FLT190 was generally well tolerated
- No infusion reactions or allergic reactions
- Transient transaminitis observed in Patient 1, but not in Patient 2
 - Transaminitis in Patient 1 observed at Week 8 and was treated with methylprednisolone + tacrolimus
 - A new prophylactic immune management regimen was implemented (per protocol amendment) at Week 3 for Patient 2
- Increases in troponin-T levels consistent with mild transient myocarditis occurred in both patients assessed as possibly related to FLT190
 - No evidence of myocarditis on cardiac MRI at time of event
 - Events did not require intervention
 - No enduring clinical sequelae noted on cardiac MRI and left ventricular ejection fraction remained normal throughout
 - No significant arrhythmias have been detected in either patient

Efficacy



Patient 1 (>2 years of follow-up)

- FLT190 absolute total dose: 4.125 x 10¹³ vg
- Subtherapeutic response
- Restarted ERT at Week 6
- Trough α-Gal A of 0.8 nmol/hr/mL (~3x baseline) at 2 years

Patient 2 (24 weeks of follow-up)

- FLT190 absolute total dose: 6.0375 x 10¹³ vg
- 46% higher absolute total dose than Patient 1; no transaminitis
- Increase in α-Gal A to mean of 3.4 nmol/hr/mL (Weeks 6-24)
- Remains off ERT

 α -Gal A = alpha-galactosidase A; ERT = enzyme replacement therapy; MRI = magnetic resonance imaging.

^{*}Assay normal range 4-21.9 nmol/hr/mL

Conclusions

- FLT190 has been well tolerated
- Novel prophylactic immune management regimen may have prevented development of vector-related transaminitis in Patient 2
- Mild myocarditis not associated with enduring clinical sequelae on cardiac MRI
 - Cardiac monitoring should be standard in gene therapy clinical trials for conditions like Fabry disease where underlying cardiac complications may contribute to treatment outcomes
- Results from lowest-dose (7.5 x 10¹¹ vg/kg) cohort demonstrate promising efficacy
 - Suggest a dose-dependent increase in plasma α -Gal A levels
 - Durable α -Gal A levels sustained for up to 2 years in Patient 1
 - Patient 2 remains off ERT as of December 22, 2021
- Third patient to be dosed with FLT190 in 7.5 x 10¹¹ vg/kg cohort by end of first quarter 2022
- As the dose of FLT190 is escalated in future cohorts, a similar dose-response effect is expected, with subsequent reduction in substrate and clearance from the tissues